Autor(es):Mostrar menos -

Monge-Fuentes, Victoria ^[1] ; Mayer, Andreia Biolchi ^[1] ; Lima, Marcos Robalinho ^{[1, 2]} ; Geraldes, Luiza Ribeiro ^[1] ; Zanotto, Larissa Nepomuceno ^[1] ; Moreira, Karla Graziella ^{[1, 3]} ; Martins, Olimpia Paschoal ^[4] ; Piva, Henrique Luis ^[4] ; Soares Felipe, Maria Sueli ^[5] ; Amaral, Andre Correa ^[6] ; Bocca, Anamelia Lorenzetti ^[7] ; Tedesco, Antonio Claudio ^[4] ; Mortari, Marcia Renata ^[1]

Afiliação do(s) autor(es)

^[1] Univ Brasilia, Inst Ciencias Biol, Dept Ciencias Fisiol, Lab Neurofarmacol, BR-70910900 Brasilia, DF - Brazil

^[2] Univ Estadual Londrina, Dept Biol Anim & Plantas, Ctr Ciencias Biol, BR-86051970 Londrina, Parana - Brazil

^[3] Univ Fed Catalao, Lab Fisiol & Farmacol, BR-75704020 Goias - Brazil

^[4] Univ Sao Paulo, Fac Filosofia Ciencias & Letras Ribeirao Preto, Ctr Nanotecnol & Engn Tecidos Fotobiol & Fotomed, Dept Quim, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP - Brazil

^[5] Univ Catolica Brasilia, Campus Asa Norte, BR-70790160 Brasilia, DF - Brazil

^[6] Univ Fed Goias, Inst Saude Publ & Patol Trop, Goiania, Go - Brazil

^[7] Univ Brasilia, Inst Ciencias Fisiol, Dept Biol Celular, Lab Imunol Aplicada, BR-70910900 Brasilia, DF - Brazil

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 11, n. 1 JUL 26 2021.
• Citações Web of Science: 0

Resumo

Parkinson's disease (PD) is a progressive and chronic neurodegenerative disease of the central nervous system. Early treatment for PD is efficient; however, long-term systemic medication commonly leads to deleterious side-effects. Strategies that enable more selective drug delivery to the brain using smaller dosages, while crossing the complex brain-blood barrier (BBB), are highly desirable to ensure treatment efficacy and decrease/avoid unwanted outcomes. Our goal was to design and test the neurotherapeutic potential of a forefront nanoparticle-based technology composed of albumin/PLGA nanosystems loaded with dopamine (ALNP-DA) in 6-OHDA PD mice model. ALNP-DA effectively crossed the BBB, replenishing dopamine at the nigrostriatal pathway, resulting in significant motor symptom improvement when compared to Lesioned and L-DOPA groups. Notably, ALNP-DA (20 mg/animal dose) additionally up-regulated and restored motor coordination, balance, and sensorimotor performance to non-lesioned (Sham) animal level. Overall, ALNPs represent an innovative, non-invasive nano-therapeutical strategy for PD, considering its efficacy to circumvent the BBB and ultimately deliver the drug of interest to the brain. (AU)

• Processo FAPESP: 13/50181-1 - Utilização de nanocarreadores contendo fármacos fotossensibilizantes e outros ativos aplicados à terapia celular e tratamento de patologias do sistema nervoso central
• Beneficiário: Antonio Claudio Tedesco
• Modalidade de apoio: Auxílio à Pesquisa - Temático